Yunkang Group (2325) H1 2024 earnings summary

Executive summary

• H1 revenue fell 20.3% YoY to RMB379.9m; net loss was RMB126.1m versus net profit of RMB48.0m, reflecting weaker demand and pricing, lower scale and increased receivables impairment.

• Medical-institution alliance testing remained the largest revenue stream; excluding early-2023 phased testing and screening revenue, management described underlying growth as high quality.

Financial highlights

• Gross profit fell 29.4% to RMB128.2m; gross margin declined to 33.7% from 38.1%.

• Operating loss was RMB107.5m versus operating profit of RMB65.9m; pretax loss was RMB131.8m versus profit of RMB50.8m.

• Net loss attributable to owners was RMB126.1m; basic and diluted loss per share was RMB0.21 versus earnings per share of RMB0.08.

• Net impairment losses on financial assets rose to RMB52.4m from RMB4.3m, including increased trade-receivable provisions; net finance costs rose to RMB24.3m from RMB15.1m.

• Operating cash flow was RMB87.6m, down from RMB168.5m; cash and cash equivalents were RMB1,289.8m at June 30, 2024. Selling expenses rose 3.5% to RMB89.9m and administrative expenses 23.8% to RMB99.7m.

Outlook and guidance

• Near-term challenges include slower routine-testing demand, market adjustments, price pressure and fierce competition; long-term healthcare demand, policy support and technology adoption offer opportunities.

• Lean operations across marketing, laboratories, supply chain, logistics and HR aim to reduce costs, with outcomes expected in H2 2024; priorities include capacity optimization, eliminating redundancy and digital tools.

• Priorities include deepening medical-institution relationships and customer services, improving operating efficiency, and continuing the Robust Project to strengthen process controls and resource use.